AU497462B2 - Avascular prosthesis from umbilical cord - Google Patents
Avascular prosthesis from umbilical cordInfo
- Publication number
- AU497462B2 AU497462B2 AU82969/75A AU8296975A AU497462B2 AU 497462 B2 AU497462 B2 AU 497462B2 AU 82969/75 A AU82969/75 A AU 82969/75A AU 8296975 A AU8296975 A AU 8296975A AU 497462 B2 AU497462 B2 AU 497462B2
- Authority
- AU
- Australia
- Prior art keywords
- segment
- vessel
- umbilical cord
- prosthesis
- vessels
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3625—Vascular tissue, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0076—Chemical modification of the substrate
- A61L33/0082—Chemical modification of the substrate by reacting with an organic compound other than heparin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Botany (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
(CONVIDTION. Byone or mor#, persons vind/or
COMMON WEALTlI .1 bPatents Act 102 TEN 0OLLAR S FU L
CONVENTON APLCATIO 11AU LPrFJ~T
82 9 69/7M I reX!X)DR. IRVINGi Is DARDI-K and DR. HARBERT DACRDIK
or of 130 Devriese Court. TenaflNwJreUie Ad&"@(m).Stat.es of America and 80.6 Washburn Street
New Jersey, Unlptod States of America. 0 APPLCATION, ACCEPTED AND A ENDMVEj'j, ALLOWED~?_ herey aplj for the grant of a Patent for an invention en i IMPIROVEMENTS IN NON-ANTIGENIC, NOTN--THROVBOGENIc INFECTION- SOC RESISTANT GRAFTS FROM UMVBILICAL COED VESSELS AND PROCESS
:':~,55)which is described in the accompanying complete specification. This application is a atPplication~s) Convention application and is based on the applications numbered()
5431462 and 563,998 Here Insert I4&meof basic ~nd fooraet orsmlrpoccinmd Unted States of Amnerica so basic dai; or
II.:23rd... d ataS
Januaary.,.1.9-7-5.. and. Aprili...
X'byaddress for service is Messrs. Edwd. Waters Sons, Patent Attorneys, Our Queen Street, Melbourne, Victoria, Australia.
DATED this day of .jR 19
DR. IRVING I. DARDIK and
Applicant (s)"ID.TEB or TqMK &eaof Ccopany and J.C4 Signatures of Ila Offcers proscribed by v by its Articles of y.7
To: THE COMMvISSIONER OF PATENTS.
COMMONVLTH OF AUSTftALIA Patents Act 1952 -1969 DECLARATION IN SUPPORT OF A CONVENTION APPLICATION FOR: A PATENT OR PATENT OF ADDITION
Insupot f he 8296975 Here insert (in In upprtof heConvenltion Application made by0).DR IRVING,. -full) N m 9aeE or Iamee of w .A Piicant oz U'
Her t for a for an invention entitled:(') iswert tit) of loweni EIVPROVENIENTS IN NON-ANT IGENIC, NON-THROMBOGENIC 0 U. INT PTION-RESISTANT GRAFTS FRCV1 UMIIICAL1 CORD VESSETS 2N a. a C AND PROCESS FOR PREPARING AND USING SAME. *0 a C WeIVNG.. DARIK and HERBERT DARDI-K U.
of')....1.9.eAYriese Court, Tenafly., Ne. Jrsy.ad.0 f3) Her Insert **@full) A (nWashburn Street. Te aneck. New Jersey; ohi h or Addr
00 do solemnly and sincerely declare as follows: 0 We arewthe applicantz for the patent. 2. The basic applications as defined by Section 141 of the Act wxs...were.. He rInsert made Uxit-ed :.Amerim sose, basic 3ountry or Coiuntries *0 follows date or so arid be aic a App Ilce .nts Applies on the day by
areuf the actual inventors of the invention referred to in the basic application or full Ile re Insert =m(s) 3.0 andA as) ,of act Invent ir(s) Other tha~n ant(s).
the actual inventor of the invention and t" cts upon which Weaeentitled t~o make the application, are as follow:'W ar
of the said~s AG() Fiull Namean of Re tual We are the assignee Inventor or Inventors,
wee 4. The basic application referred to in paragraph 2 of this Declaration xxxc the first applications made in a Convention country in respect of the invention the subject of the application.
DECLARED e..J.ersay w
day of. f.gwqu 197,8....
Signature X of Applicanta Applicants.
ItE -MOF PATEN' MI s Io.,B CCo
AIe (11) AU-B 82969/75
(12) PATENT SPECIFICATION ABRIDGEMENT (19) AU
(21) 82969/75 497462 (22) 11/7/75 (23) 11/7/75 (24) 23/1/75 (31) 543462 (32) 23/1/75 (33) US 563998 4/4/75 US (43) 13/1/77 (44) 14/12/78 (51)2 A61F 1/24 (54) A VASCULAR PROSTHESIS FROM UMBILICAL CORD DARDIK, DR.I.I. DARDIK, DR.H. (74) EDWD. WATERS SONS, MELBOURNE (56) 80968/75 476070 A61F 1/00 A01N 1/02 40917/72 457613 A61F 1/24 (57) A method of use of the prosthesis is also claimed. CLAIM 1. A vascular prosthesis, comprising a flexible segment of a mammalian 'umbilical cord vessel that has been hardened and shaped, and which has a low antigenicity and low thrombogenicity.
47/1
~y 4~LO~
Form COMMONWEALTH OF AUSTRALIA
PATENTS ACT 1952469
82969/75 Class I t. Class Applicatioi Number: 11 Lwnged: tb~
::ovplete Specification Lodged: Accepted: amndneipti Secti-m 49.
aa4 ts ixrde Under-
ortfor <,inn. I Published: *arority:
jUdiated Art:
:'Name of Applicant: DR. IRVING I. DAFLDIK and DR. HERBERT DARDIK
'Address of Applicant: 130 Devriese Co)urt, Tenafly, New Jersey, United States of' America and 806 Washburn Street, Teana.ck, New Jersey, United States of America Actual inventor: DR. IRV ING I. DABDIK and DR. HERBERT DAIRDIK
Address for Service: EDWD. WATERS SONS, 50 QUEEN STREET, MELBOURNE, AUSTRALIA. 3000.
Complete Specification for the invention enutitled:
IMVPROVEMENTS IN NON-ANT IGENIC, NON-THROMB0GENTIC INFECTION-RESISTANT GRAFTS FROM UMBILICAL CORD VESSELS AND PROCESS FOR PREPARING ANTD USING SAME.
ihe following statement isa full description of this invention, including the best method of performing it known to:u
1.
NON-ANTIGENIC, 82969 497.46 NON-THROMBOGENIC INFECTION-RES'ITANT
A major problem in vascular reconstructive surgery is
the provision of blood to organs and tissues the blood vessels
of which are inadequate either as the result of congenital
defects or acquired disorders such as trauma, arterial sclerosis
or other diseases. Initially, arterial homografts (human
arteries) were used to restore continuity but limited supply,
inadequate size ranges, development of aneurysms and athero-
sclerosis necessitated the search for a better substitute.
S: Artificial grafts of porous and pliable plastic cloth
have been made but these suffer from the following problems: *0 1. Infection in a foreign body graft is catastrophic,
often leading to hemorrhage, seps.is nd death.
2. The inner lining is thrombogenic, predisposed to
clotting of the graft and distal embolism of the 0*
Sclot.
3. The rigidity of cloth grafts may result in twisting
and kinking, especially in areas of crossing a joint.
4. Because of clotting difficulties, smaller caliber
0 artificial grafts are frequently unsuccessful.
Other types of grafts which have been tested with
82969/5 greater or lesser degrees of success are bovine heterografts,
collagen tubes created within the recipient patient, saphenous
veins both as autografts where the patient is the donor and as
allografts or homografts where another human is the donor.
These various substitutes also give rise to problems of unavail-
ability, small size, non-uniform caliber, time required for
harvesting, intraluminal valves, easy twisting leading to
occlusion and taper ia the wrong direction. This last problem
is particularly acute where saphenous veins are used since the
veins must be reversed as to the direction of flow of blood
therethrough when substituted for arteries. In view of the es.. c 0*
S. difficulties encountered, it is evident that there is pressing S *6 S
S S need for a vascular prosthesis which is free of the problems S.
enume ated above. In addition, it would be highly desirable S V- @0 0 S P that such prostheses could be stored and kept at hand in a S
S wide variety of size's and shapes immediately available for use.
0 The human umbilical cord contains structures which SO
S. may be used for grafts in the vascular system or other body
conduits in mammals including man. The umbilical cord contains 0
a vein and two arteries surrounded by Wharton's jelly. Both 0
arteries and the vein are suitable for use in surgery. Composite
-2-
i. ii_.i..i grafts and patches can be made in various sizes and shapes.
Arteries and veins removed from umbilical coras may be
Sused fresh or as a stored homograft in either frozen or
Ob chemically preserved form. Treatment with antibiotics or
00 other means for sterilization may be carried out. Although
the antigenicity of these members is low, treatment with
S* enzymes may be carried out to eliminate any antigenic
substances.
Alternatively, the entire segment of umbilical cord
can form the prosthesis, thus providing addition;i strength to the segment carrying the bloodstream.
In general, the cord is somewhat cboiled and the
arteries therein are twisted arotd the vein. Consequently,
mechanical or chemical techniques to straighten out the vein and arteries may be necessary.
In preparation for use of th- vein and arteries,
Wharton's jelly may be removed either manually or by flushing
out with saline solution. A mandrel, which may be shaped, a
preferred shape being a taper, may be inserted into the vein
after which the vein and the arteries may be dissected Yeadily out of the umbilical cord itself. As aforenoted,
the vein and the arteries may be used fresh or frozen. In
addition a tanning treatment as with an aldehyde can be
used to stiffen the material, one advantage of such treatment
beirg uhat the tanned member will retain the shape of the
mandrel. Glutaraldehyde is z. preferred tanning agent. Prior
to use of the tanned member,
82969n5 residual traces of glutaraldehyde are removed by treatment with
appropriate chemical reagents, a preferred reagent being
glutamic acid. It has been found that such treatment with a
tanning agent and a reagent to remove residual traces of same
yield a product of low antigenicity and thrombogenicity.
The advantages of th umbilical vessels, whether
fresh or preserved, for use as a conduit or a patch or rein-
forcing member are as follows:
1. Ready availability.
2. High flexibility with freedom from tendency to
06*0 kink. S. 0
*1.0 3. Marked strength, particularly in the smaller S. .e SI 9* diameter vessels.
S 0* S 4. Highly smooth, natural inner lining with extremely o 6
low clotting tendency.
Low tendency to become infected. S S
S 6. Low antigenicity. 55
7. Controllable diameter. OS 0 S0 8. Size selection available for both large and
small vessels.
0 9. Sufficient length for virtually any use. 0 10. Adaptability to a wide variety of shapes including
both tapers and curves.
11. Compatability with an outer support in the form
of a mesh for reinforcement of larger vessels
-4-
82969n5 to be used under pulsatile conditions.
12. Use as a coating for promoting the healing of surface
trauma such as wounds and burns.
Accordingly, an object of the present invention is an
improved material for use as a vascular prosthesis, a rein-
forcement for organs in the form of patches, for reinforcement
of anastomases, and for promoting the healing of surface trauma.
Another object of the present invention is a method of
employing the vein and arteries from an umbilical cord in
surgical procedures.
A further object of the present invention is a method
of shaping veins and arteries from an umbilical cord in
o preparation for use in surgical procedures.
An important object of the present invention is a method
of preparing and preserving veins and arteries from umbilical
cords so that they may be stored in readiness for use in surgical
procedures.
A significant object of the present invention is a
material in the shape of conduits or patches using veins and
o* arteries from umbilical cords as the source of same, said
material having low antigenicity, low thrombogenicity and
being highly resistant to infection.
Still other objects and advantages of the
invention will in part be obvious and will in part be
M apparent from the specification. The invention accordingly provides a flexible,
C* hardened and shaped segment of a mammalian umbilical cord tD vessel for use as a prosthesis in mammals, said segment
being of low antigenicity and thrombogenicity.
The invention also provides a process for
preparing a flexible segment of an umbilical cord for use as
a prosthesis, comprising the steps of separating and removing at least one of the
principal blood vessels from an umbilical cord;
hardening said blood vessel by means of a
reagent; shaping said vessel.
5a
829 69 5 a CC A 1 1
in part obvious and will in part be apparent from the
specification.
The invention aordingly comprises the several steps
and the relation of one or more such steps with respect to
each of the others, and the article pos sing the features,
properties, and the relation of elements, which e exemplified
in the following detailed disclosure, and the scope of i 4I_7r. .r41n4> 1l Ai it 1 omna h ~r-r
BRIEF DESCRIPTION OF THE DRAWINGS oo~lo I0 o I' A* 0 S For a fuller understanding of the invention, reference 1 0
is had' to"the following desript ion taken in c-onne ction with -the"'
accompanying drawings, in which: L *0 0 I 0 Fig. 1 is a view in perspective of an umbilical cord 0 0
00 prior to. treatment; 000
t Fig. 2 is a sectional view of an umbilical cord vessel I i !o on a cylindrical mandrel;
Fig. 3 is a view in partial section of an umbilical cord 00 O0 vessel pressed against the interior of a mold hydraulically; 00
Fig. 4 is a sectional view of an umbilical cord vessel 0 0
000000 0 0 on a tapered mandrel;
Fig. 5 is a view in perspective of a segment of an
umbilical cord;
-6-
dlYyl Lr~*iii-.i;;n2.
82969n5 Fig. 6 is a side view of a vessel reinforced, at a seam
by a segment in the shape of a patch;
Fig. 7 is a sectional view of an anastamosis reinforced
by a segment in the form of a strip; and
Fig. 8 is a view in perspective of an eyeball wherein
the region of attachment of a retina to the interior of an eyeball
is reinforced by an eye sling, the sling being formed of an
umbilical cord vessel in accordance with the present invention.
The following example illustrates the technique of
.9 vascular surgical interposition of an umbilical cord vessel
deriVed' "Erom the human' into:the. Abdominal aorta :of an.an imal.,-
The animal, in this case a baboon, was prepared under general .9 anesthesia and sterile conditions for making an abdominal incision 0
The baboon was prepared and shaved and a longitudinal incision S
was made in the midline of the abdomen. The incision extended .9
0r from the xythoid to the pubic area and was carried down through 9090 the midline and into the peritoneal cavity. Bleeding vessels 9
were clamped and ligated with 3-0 polyglycollic acid sutures.
The peritoneal cavity was entered and the viscera and bowel were 9
explored for any other diseases. The animal was found to be
normal. The bowel and viscera were walled off with cloth pads
82969nm and retractors. The peritoneum overlying the aorta was incised
and the aorta immobilized by sharp and blunt dissection. Lumbar
arteries were individually clamped and ligated with 3-0 silk
suture so that the segment of abdominal aorta extending from
the infra-renal arteries to the bifurcation of the aorta was
immobilized. The entire segment of abdominal aorta was thus
made available for transplant of the umbilical cord. During
preparation of the abdominal aorta of the baboon, another
investigator had taken the umbilical cord of an infant (human)
that had been born two hours prior to the surgical intervention
of the baboon. The cord had been delivered and taken in its S* entirety and transported in sterile saline solution, packed in ice
The purpose of freezing the umbilical cord in ice was to prevent oo-
any further decomposition of the cord structure. The cord,
prior to insertion, was washed and irrigated numerous times
with sterile Collins solution with antibiotics, in this particular
instance, 1% cephalosporin solution and 25,000 units of bacitracin
0 per liter of solution. The blood was thoroughly washed out from
within the vessels of the cord and the cord was also irrigated 0.
with a 1% heparin anticoagulant solution. Following this thorough
cleansing of the cord, one end of the umbilical vein within
the cord which was to be used as the transplant was clamped
-8-
m
-f-
82 9 69 with a clamp and through the other end a red rubber catheter,
No. 14 French, was introduced and the vein was distended. At
this point a suitable segment of umbilical graft, approximately
centimeters in length, was selected for excision. A mandrel
was placed in the vein and the remainder of the cord was cut away.
This segment of vein was then sterilely handled and placed into
the operating field. At this point the animal was heparinized
with 2,500 units of aqueous heparin given intravenously. The
abdominal aorta was then clamped proximally and distally to
the segment to be resected. A segment of approximately 3
centimeters in length was resected from the abdominal aorta S
and an end-to-end anastomosis was performed between host aorta
I and donor umbilical vein, first -using continuous 6-0 prolene
suture which is a nylon monofilament suture. The distal
anastomosis was then performed following flushing of the aorta
to rid it of any clot material and debris. Following completion
.i of anastomosis the distal and then the proximal clamps were
removed. It was noted that there was no bleeding between the
interstices of the sutures, which is unusual, and is felt to
be due to the strength and self-sealing gelatinous qualities of the cord structure. Excellent pulses were ncted to be
present in the graft as well as the distal iliac vessels. The
-9-
;11-
82969n area was lavaged with saline and suctioned. The retroperitoneum
was closed with interrupted 3-0 polyglycollic acid sutures and
the viscera was replaced. The animal, throughout the procedure
thus far, was stable; the respiration and vital signs were normal.
The abdominal wall was then closed in layers using continuous
0 silk for the posterior fascia and peritoneum and interrupted
silk sutures for the anterior fascia. The skin was approximate
with continuous 3-0 nylon suture. The anesthesia used in this
procedure was nembutal. The blood loss estimated during the
procedure was approximately 50 to 75 cc. The animal tolerated
the procedure wel" and awoke within 30 minutes. Postoperatively
S".on the following day the animal was sitting and walking in its
cage, and on the third postoperative day was eating its regular.
diet and was allowed out of its cage to roam around and climb up an
down the walls, and appeared to be in excellent health. The legs
were warm and pulses were intact in the extremities.
S: A number of procedures will become apparent to those
skilled in the art. If desired or necessary, the vein or artery
of the umbilical cord may be split longitudinally and formed into composites of larger diameter. The umbilical cord vessel
or a portion thereof whether tanned or fresh may be used to
reinforce, support or seal a weakened area or defect of any
body structure, such as the heart, the heart valves or urinary
bladder, or to cover a surface trauma to promote healing thereunder
Such procedures are included within the scope of the claims.
Before removal from the umbilical cord, the vessels,
especially the vein, appear to be almost closed and quite small
as can be seen in Fig. 1 which is a perspective view in enlarged
scale of a portion of an umbilical cord. The umbilical cord
vein carries the reference numeral 11 and the arteries the
reference numeral 12. These vessels are surrounded by
Wharton's jelly, as aforenoted. Moreover, the arteries 12
are twisted and coiled about vein 11 and also contain the valves
of Hoboken. These are some of the factors which have
made it unobvious to use these vessels as tubular grafts., Mention
has already been made of the fact that the insertion of a mandrel
into the vein 11 aclitates the removal 6f the remainder of
the umbilical cord. However, arteries 12 can also be carefullydis
sected from the umbilical cord and mounted upon mandrels. When
this is done and they ar. properly tanned, the valves of Hoboken
are eliminated and vessels smaller than 1 mm in inside diameter
can readily be prepared and permanently shaped by the use of
appropriate tanning solution. The umbilical cord vein is
substantially larger than the arteries and can be stretched on
a mandrel so that vessels as large as 1 cm in inside diameter
can be prepared. Such vessels can, of course, be cut open and
-11- -II
82969n5 laid out flat in which condition they are suitable as patches
for reinforcement of organs, for supplementation of anastomoses
and for coverings over surface trauma.
After dissecting out the desired vessel or vessels
and clearing of residual blood, they are irrigated for several
minutes with a hardening agent, preferably 3 10 minutes. This step effects partial elimination of Hoboken's valves from the
arteries. The hardening agent found most suitable is the class of aldehydes. Examples are formaldehyde, glyoxal, dialdehyde starch and: glutaraldehyde, with glutaraldehyde being the best
from the standpoints of elimination of any traces of antigenicity
"o land thrcmbogenicity and convenience, with a solution of dialdehyde
starch. being next best. The concentration of the glutaraldehyde
solution should be between about 0.15% and The concentratio of dialdehyde starch should be between about 0.5 and 2.0% by weight
At lower concentrations the glutaraldehyde solution does not rendel
the material non-antigenic, while at higher concentrations the reaction is too rapid and embrittles the wall of the vessel.
After irrigating a vessel with a hardening solution,
the vessel is slipped onto a mandrel of appropriate shape. The e 0vessel on the mandrel is then placed in a tank (not shown) of
hardening solution for about 15 to 45 minutes, during which time the vese.conforms to the shape of the mandrel. A preferred the vessel. conforms to the shape of the mandrel. A preferred
82969/75 solution for hardening the vessel is 0.5% glutaraldehyde
buffered with 1% sodium bicarbonate so that the pH of the
solution is between 7.5 and 8.5. The hardening agent causes
the vessel to conform to the shape of the mandrel and also
increases the strength of the vessel material. A vein 11
is shown on a cylindrical mandrel 15 in Fig. 2. Another means of shaping a vessel is shown
in\ig. 3 in which a vein 11 is inserted in a tubular mold 18,
end 19 of vein 11 being closed with stopper 21. The other end
22 of vein 11 is connected to hose 23 for introduction of harden-
ing solution 16 under moderate pressure. The pressure of the hardening solution 16 forces vein 11 against the interior
of mold 18 to conform to said interior. This process results
in a vessel having a smoothed exterior. S: The practice of shrinking a vein or artery
onto a cylindrical mandrel 15 as in Fig. 2 or a tapered mandrel 25 as in Fig. 4 has the advantage that any internal irregularities such as the valves of Hoboken are eliminated,
the reference numeral 24 indicating a vessel segment where the vessel may be either a vein or an artery. Arteries of
small diameter are particularly valuable for replacement
-13-
Yi;iil ii i
S: of blood vessels in the body. In this context, the umbilical <Cs cords of the larger mammals, while not so readily available as
I those of humans, contain large. vessels so that larger and
00 thicker-walled vessels and patches become available through use
iof vessels from such sources. Also,.the small mammals provide vessels of smaller diameter, such vessels being needed for
specialized applications such as in fingers and toes.
It. should be noted that for use of segments
Itreated in accordrnce with the present invention in pulsatile
!blood vessels smaller than about 2 mm internal diameter, rein-
forcement with artificial mesh is unnecessary. This follows not
only from the fact that tubes of smaller diameter can withstand
higher pressure, in general, but from the fact that in collapsing
the vessels, the wall thickness is increased. Soaking the vessel in alcohol prior to the aldehyde treatment results in a stiffer o, S. 'vessel.
After hardening.the vessel, it is rinsed to remove,
most of the hardener. A 1% solution of NaHCO 3 may be used. It is
then desirable to treat the vessel or segment for a period of
;30 45 minutes with a reagent which reacts with residual aldehyde.
iSuitable materials are amino acids, alkali salts thereof and oxidizing agents in dilute form such as peroxides, peracids and 06
hypochlorites. The amino acids as sodium salts, and preferably of'
*;L-sodium glutamate, L-sodium alanine, L-sodium phenylalanine
;and L-cysteine are particularly suitable for this purpose
-14-
1 i ;L_ r
82969/75 because they are antithrombogenic, the best of the above being
the glutamate. The mechanism is believed to depend on
condensation of the amine group of the aminoacid with the
carb'nyl group of aldehydes. This leaves the carboxyl group
of the condensate free to ionize and impart a negative charge
to the surface of the vessel. Negatively charged surfaces
are known to be antithrombogenic. Although the preferred method of storage subsequent
to hardening and shaping of the vessel is in a dilute solution of
aldehyde,, it is advantageous to treat the vessel with an
amino-acid after hardening to eliminate aldehyde as indicated. r* 0* @0 A suitable method of storage of tanned vessel S**
segments is in a dilute solution of aldehyde, 0.5% glutaraldehyde o 0 being preferred. Some further hardening of the segment takes 0
0 place over a period of 4 6 days. However, the extent of
hardening during storage is small and can readily be compensated
for in the principal hardening stage. In preparation for implantation, after storage, the
segment is rinsed, as in sterile saline or 1% NaHC0 3 solution. 0 0@!
It is preferably treated again with sodium L-glutamate or one
0. 0.. of the other aforenoted compounds to eliminate residual
aldehyde..
L i~-L~i-i^CY ^_iii__iiii i
*1 8296975 An alternate method of storage is in a solution
of 40 50% aqueous alcohol containing about 1% of propylene oxide.
Treatment of segments stored by this method with reagent to
remove aldehyde is, of course, unnecessary.
As will be recognized, a substantial number of
variations on the procedures outlined above are feasible.
Thus, after flushing out the vein in the umbilical cord, a
mandrel, either tapered or straight, may be inserted into the
vein, the cord frozen, the mandrel placed in a chuck and all
elements other than the vein cut away on a lathe. In the
process, the exterior of the vein may be cut so that the wall
thickness becomes uniform or, tapered, if so desired. As 0*
*C would be expected, the vessel or segment must be rendered
sterile after subjection to such manipulation. Conventional 559
c *1 non-destructive techniques such as radiation, antibiotics
and elevated temperature are used. Also, elevation of the
0 temperature up to as high as 60 C during the tanning reaction
I increases the rate of tanning.
for The same technique can be used
removal of residual traces of tanning agent.
Another variation is to slit the vein open and
lay it out flat. The use of a flat mandrel facilitates the
formation of flat segments. The vessel may then be cut into
-16-
U i
82969n5 segments 20 of any desired size as shown in Fig. 5, such
iisegments to be i"sed as reinforcemehts or patches. One use of
i!such a patch is shown in Fig. 6 wherein a vessel 26, which may
be a portion of a bowel which has been sewn together to form
a seam 27, using sutures 28. This repair of the vessel 26 can
ibe reinforced by placing a segment 29 as a patcn over seam 27
!and suturing the patch over vessel 26.
The function of such a patch is greater than
imere reinforcement. As is well known, in stitching together
i portions of walls of organs in the body, it is necessary that
Sthe sutures not be pulled too tight and that the stitches not be
too close, else the blood supply to the wall of the organ may i I, be cut off in which case gangrene may supervene. As a result, il using standard techniques, there may be leakage through the
:suture line in the wall. It is for this reason that drains ee
'are so commonly used. Reinforcing the seam with a patch as
'shown in Fig. 6, greatly decreases if not completely eliminates
this danger.
Another version of the use of a segment
prepared in accordance with the present invention is shown in
Fig. 7 which represents an anastamosis in a bowel 31. In
accordance with the usual surgical procedure, the two ends 32 0
land 33 of bowel 31 are turned inward and the ends are then
i sewn together with suture 34. A segment 36 is then sewn around
82969n5 the join between bowel ends 32 and 33, thereby eliminating
or greatly reducing the danger of seepage of bowel contents
into the abdomen. Needless to say, although Fig. 7 shows
only a. single turn of segment about the bowel, two or more
turns about the bowel could also be taken.
A plurality of segments may be used in certain
applications such as for lining the pericardium of the heart,
or a heart valve, or for covering an artificial implant such as a pacemaker. Segments may also be used in plastic surgery
as an inert reconstructive material. *lm S S e 1
S Although the tensile strength of a hardened
vessel is only moderate, it has other characteristics which S.
0 make it highly desirable for use surgically. These are the
aforenoted non-antigenicity and non-thrombogenicity as well
as characteristic flexibility, slipperyness and complete S 0* S. compatibility with body organs and vessels. 0
There is a wide variety of surgical procedures S. S.
in which cord segments can be used to great advantage. It 0@
-18-
IYll.ryj-L-i I i se 82969/7 ias already been mentioned that a segment can be used to ii reinforce a seam and an anastamosis. It can also be used to reinforce a weak portion or a defect in the wall of an organ
Ssuch as an urinary bladder. A segment can be shaped to form
San artificial conduit between the urinary.bladder and the skin.
:A most important use is as a retinal eye sling. The need for a
j sling arises in the surgical procedure for repairing a detached
retina. The way in which an eye sling is used is shown in Fig. 8
I wherein the reference numeral 47 generally indicates an eyeball.
SThe pupil 48 of the eyeball 47 is shown and the area where a
repair has been effected surgically is shown at 49. The region
of repair must be held under pressure until the retina attaches
i itself permanently to the eyeball. For this purpose a sling 51
o: is wrapped around the eyeball so that the eyeball is compressed
against the retina in the interior thereof. This generally 4o* *6
requires that the internal pressure in the eyeball be increased
Sby about 30 mm of mercury.
Up to the present time retinal eye slings have 0
S,j been made of silicone plastic or fascia lata. The former
I carn erode the eyeball and precipitate infection. Consequently, 0 ,i
i a certain fraction of such procedures fail and, in such cases,
Sblindness can result. Use of fascia lata, on the other hand,
Snecessitates a prior operation in order to obtain the material.
19-
8296975 SSubstitution of a segment prepared in accordance with the
present invention eliminates these difficulties. The material
Sis completely compatible with the body and has no tendency to
erode the eyeball.
Another important use for patches derived
from umbilical cord vessels is in connection with skin grafting.
A patch can be placed in position over a burned,or traumatized
area, even in the presence of infection. In many cases even
a dressing is not needed. The patch "takes" quickly. Healing,
including clearing of underlying infection,proceeds rapidly
under the patch and with no need for the usual change of
surgical dressings. The patch sloughs off when healing is I.
sufficiently advanced. Of major importance, these grafts
S. will persist for several months while healing proceeds. S. The use of umbilical cord vessels, whether
from humans or from other mammals, as can be seen from the
above, presents numerous advantages. The supply is virtually
unlimited and the treatment needed for rendering the vessels
appropriate for use in surgery is simple. Also, many variations
are possible in order to meet specific and varied needs. As
a result, sterile cord vessel segments can be produced-in
unlimited supply and at relatively low cost. They can be stored
I indefinitely and in a variety of shapes and thicknesses to meet
829 6975 virtually any need. Assuming they are stored in dilute
glutaraldehyde solution, they need only be rinsed in sterile
water or saline solution or dilute NaHCO 3 preparatory to use.
If desired, they can be further rinsed in sodium-L-glutamate
to eliminate any residual aldehyde.
In preparation for tanning and shaping, cleansing,
rinsing or irrigating solutions may be passed through the vein
and arteries of the umbilical cord, solutions which may be
employed including water, sterile saline solution, Ringer's
lactate solution, hydrogen peroxide, sodium bicarbonate solution,
alcohol, and transplantation perfusate solutions. Antithrombo- SO OS S. genic agents whi be used to treat the graft include i
L-sodium glutamate, L-alanine, L-phenylalanine, L-cysteine S
S and L-lysine. These compounds are also suitable for treating C
vessel segments after tanning in order to remove residues of
S, the tanning agent. S.1
Wharton's jelly may be removed mechanically
or chemically using hyaluronidase to dissolve the hyaiuronic
acid which comprises the jelly. Moreover, saline solution 0
is also effective for this purpose.
Mandrels used for shaping vessels may be of glass, IS silicone plastic, stainless steel or any other material inert
to the graft vessel and the chemicals used in the process. The
mandrel may be straight or curved, solid or hollow, cylindrical
or tapered and smooth or rough on its surface, as desired.
U*UXLYII- i_~l~YLlj~- i ll lii~lY;~-IWC.... i_ i; -91-
.29 69ns Among aldehydessuitable for tanning agents are
glutaraldehyde, dialdehyde starch and formaldehyde, as well
anhydrous alcohol, glyoxal and chromic oxide.
In addition to the amino acids listed above for
removing residues of aldehyde tanning agents, mild oxidizing
agents can also be effective. Examples of such agents are
dilute hypochlorite solution and dilute peroxide.
Particularly where the larger vessels are to be
used, especially those over about 5 mm in inside diameter,
it is desirable to reinforce the vessel. In general the vessels
are reinforced by the use of an exterior coating of a mesh
support. Both polyesters and fluorocarbon plastics can be used,
with the polyesters being preferred. Commercially available
Mersilene mesh having wide interstices (0.5 2.0 mm) may S.
I be wound around the vessel in order to give the graft added e
S.strength and support, the mesh actually embedding itself into
the outer wall of the graft. A preferred form of the mesh
is as a preformed sleeve.
Grafts reinforced by mesh can be tested for leaks
and strength by attaching them to a pulsating machine and passing
I. solution therethrough at a pressure of .150 to 300 mm of mercury.
It will thus be seen that the objects set forth
S* above, among those made apparent from the preceding description,
are efficiently attained and, since certain changes may be
made in carrying out the above process and in the article set
i i;
82969 ns forth without departing from the spirit and scope of the
invention, it is intended that all matter contained in the
above description and shown in the accompanying drawings shall
be interpreted as illustrative and not in a limiting sense.
It is also to be understood that the following claims
are intended to cover all of the generic and specific features
of the invention herein described, and all statements of the
scope of the invention, which, as a matter of language, might
be said to fall therebetween.
ee
-23- 0
See
0*
ji
9
-11 iL 11-r/;ilii~__ i- Y1 W
Claims (1)
- The Claims defining the Invention are as follows:-1. A vascular prosthesis, comprising a flexibleSsegment of a mammalian umbilical cord vessel that hasbeen hardened and shaped, and which has a low anti- i*C genicity and low thrombogenicity.2. The prosthesis as defined in claim 1, whereinsaid. vessel has been removed from said umbilical cord.3. The prosthesis as defined in claim 1, wherein 0 said vessel is within said umbilical cord.4. The prosthesis as defined in claim 1, wherein0 said segment is tubular in shape and is reinforced by apliable, plastic cloth mesh around the exterior thereof.s' 5. A process for preparing a vascular prosthesisconsisting of a flexible segment of umbilical cord,comprising the steps of:separating and removing at least one of the principal blood vessels from said umbilical cord;hardening said blood vessel by means of areagent;shaping said vessel.6. A process for preparing a vascular prosthesisconsiscing of a flexible segment of umbilical cord,comprising the steps of:hardehing one of the principal blood vesselswithin said segment by means of a reagent;shaping said vessel.7. The process as defined in claim 5 or 6, wherein said segment is hardened by one of the aldehydes,glutaraldehyde, formaldehyde, dialdehyde starch and glyoxal.8. The process as defined in claim 5 or 6, whereinC said segment is hardened by bringing same in contactq with a solution of glutaraldehyde at a concentration offrom 0.15% to 0.6% by weight for a period of aboutto about 45 minutes.9. The process as defined in claim 8, furtherScomprising the steps of washing the aldehyde-treatedsegment with water, saline, or dilute sodium bicarbonateto remove aldehyde and then with a reagent to remove anyresidual aldehyde, said reagent being an amino acid, analkali salt of an amino acid, an amine, a hydroxylamine,a peracid, a peroxide, or a hypochlorite.The process as defined in claim 5 or 6, furthercomprising the step of storing said segment in a sterilesealed container.11. A mebhod of repairing, augmenting, or replacinga body conduit or repairing or augmenting an organ,which comprises suturing or otherwise securing a portionof a vasr ilar prosthesis as claimed in claim 1 into oronto the wall of such conduit or organ.12. The method as defined in claim 10, wherein saidsegment is tubular and is reinforced by a fabric mesharound the exterior of said segment.DATED THIS 16th DAY OF October, 1978. DR. IRVING I. DARDIK and DR. HERBERT DARDIK.EDWD. WATERS SONS, Patent Attorneys, Queen Street, MELBOURNE. AUSTRALIA. 25r 4 hO
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/543,462 US3974526A (en) | 1973-07-06 | 1975-01-23 | Vascular prostheses and process for producing the same |
| USUS543462 | 1975-01-23 | ||
| US05/563,998 US3988782A (en) | 1973-07-06 | 1975-04-01 | Non-antigenic, non-thrombogenic infection-resistant grafts from umbilical cord vessels and process for preparing and using same |
| USUS563998 | 1975-04-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU8296975A AU8296975A (en) | 1977-01-13 |
| AU497462B2 true AU497462B2 (en) | 1978-12-14 |
Family
ID=27067341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU82969/75A Expired AU497462B2 (en) | 1975-01-23 | 1975-07-11 | Avascular prosthesis from umbilical cord |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JPS521011A (en) |
| AT (1) | ATA541675A (en) |
| AU (1) | AU497462B2 (en) |
| BR (1) | BR7504424A (en) |
| CA (1) | CA1055843A (en) |
| DE (1) | DE2531588C2 (en) |
| DK (1) | DK140086B (en) |
| ES (1) | ES441295A1 (en) |
| FR (1) | FR2298312A1 (en) |
| GB (1) | GB1493459A (en) |
| IL (1) | IL47667A (en) |
| NL (1) | NL7508306A (en) |
| NO (1) | NO752465L (en) |
| SE (1) | SE7508047L (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2902434C2 (en) * | 1978-01-26 | 1986-10-16 | Arthur August Roseville Minn. Beisang | Method of manufacturing a blood vessel implant |
| FR2502489A1 (en) * | 1981-03-30 | 1982-10-01 | Ufim I Glaznykh Bolezn | Homo:transplant material, esp. for conjunctiva - comprising retro:peritoneal fascia tissue |
| FR2523810B1 (en) * | 1982-03-23 | 1988-11-25 | Carpentier Alain | ORGANIC GRAFT FABRIC AND PROCESS FOR ITS PREPARATION |
| ZA843751B (en) * | 1983-06-10 | 1984-12-24 | University Patents Inc | Body implants of extracellular matrix and means and methods of making and using such implants |
| US4681588A (en) * | 1983-10-20 | 1987-07-21 | Vettivetpillai Ketharanathan | Biomaterial |
| US4674488A (en) * | 1985-03-04 | 1987-06-23 | American Hospital Supply Corporation | Method of treating bone fractures to reduce formation of fibrous adhesions |
| US4786287A (en) * | 1986-10-10 | 1988-11-22 | Baxter Travenol Laboratories | Process for decreasing residual aldehyde levels in implantable bioprosthetic tissue |
| CN113733532B (en) * | 2021-08-25 | 2022-10-11 | 中山大学 | Flexible polyester patch and preparation method and application thereof |
-
1975
- 1975-07-07 GB GB28540/75A patent/GB1493459A/en not_active Expired
- 1975-07-08 IL IL47667A patent/IL47667A/en unknown
- 1975-07-09 CA CA231,154A patent/CA1055843A/en not_active Expired
- 1975-07-09 NO NO75752465A patent/NO752465L/no unknown
- 1975-07-11 BR BR7504424*A patent/BR7504424A/en unknown
- 1975-07-11 AU AU82969/75A patent/AU497462B2/en not_active Expired
- 1975-07-11 NL NL7508306A patent/NL7508306A/en not_active Application Discontinuation
- 1975-07-11 FR FR7521940A patent/FR2298312A1/en active Granted
- 1975-07-14 DK DK318975AA patent/DK140086B/en unknown
- 1975-07-14 AT AT541675A patent/ATA541675A/en not_active Application Discontinuation
- 1975-07-14 JP JP50085413A patent/JPS521011A/en active Granted
- 1975-07-14 SE SE7508047A patent/SE7508047L/en unknown
- 1975-07-15 DE DE2531588A patent/DE2531588C2/en not_active Expired
- 1975-09-26 ES ES75441295A patent/ES441295A1/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IL47667A (en) | 1978-04-30 |
| IL47667A0 (en) | 1975-10-15 |
| DK318975A (en) | 1976-07-24 |
| GB1493459A (en) | 1977-11-30 |
| CA1055843A (en) | 1979-06-05 |
| DK140086B (en) | 1979-06-18 |
| DE2531588C2 (en) | 1983-11-03 |
| FR2298312B1 (en) | 1978-07-28 |
| AU8296975A (en) | 1977-01-13 |
| ES441295A1 (en) | 1977-03-16 |
| NO752465L (en) | 1976-07-26 |
| ATA541675A (en) | 1979-02-15 |
| FR2298312A1 (en) | 1976-08-20 |
| DK140086C (en) | 1979-11-12 |
| JPS521011A (en) | 1977-01-06 |
| SE7508047L (en) | 1976-07-26 |
| NL7508306A (en) | 1976-07-27 |
| JPS6122981B2 (en) | 1986-06-03 |
| DE2531588A1 (en) | 1976-08-05 |
| BR7504424A (en) | 1976-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU500233B2 (en) | Manipulator | |
| AU496790B2 (en) | Pourer-stopper | |
| AU1108376A (en) | Polyhemoglobin | |
| AU1230276A (en) | Amidinoureas | |
| AU1441776A (en) | Thieno-pyridines | |
| AU498709B2 (en) | Drill | |
| AU1829576A (en) | Hydropyrimidines | |
| AU1667476A (en) | Chroman-4-ones | |
| CA1029050A (en) | Tunneling equipment | |
| AU500698B2 (en) | Amino-alkyl-diphenyl sulfides | |
| AU501016B2 (en) | Propargyl-2 phenylamino-2-impazolines | |
| AU1128976A (en) | Magneto-alternator | |
| AU504002B2 (en) | Drill | |
| AU8296975A (en) | Avascular prosthesis from umbilical cord | |
| AU1722876A (en) | Antimacassar | |
| CA1032387A (en) | Bookcovers | |
| AU506794B2 (en) | Lubricants | |
| AU1408076A (en) | Lysolipin Antibioties | |
| CA1027606A (en) | Multiduct connector | |
| AU1393076A (en) | Dihydromocimycin | |
| CA1010780A (en) | Blasting plug | |
| AU510595B2 (en) | Trenching apparatus | |
| AU500420B2 (en) | 6-aminomethylated 3-oxygenated chloest-5-enes | |
| AU498354B2 (en) | 1-azidoalkylimidazoles | |
| CA1030567A (en) | Earth moving equipment |